Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 3, Issue 2, Pages 204-208Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S1471-4892(03)00002-X
Keywords
-
Categories
Ask authors/readers for more resources
Recent advances have identified novel small molecule inhibitors of the transforming growth factor-beta (TGF-beta) type I receptor kinase as a potential therapy in organ remodeling diseases, such as chronic renal disease. Because TGF-beta is central to the progression of fibrosis, selective inhibition of this signaling pathway could provide a novel treatment in many fibrotic diseases. The rationale for inhibition of TGF-beta signaling in renal disease includes prevention of fibrosis, tubular dedifferentiation and vascular effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available